Brief: Abionyx Pharma Receives FDA Orphan Drug Designation For CER-001 For LCAT Deficiency

Abionyx Pharma SA

29/03/2022 17:25

March 29 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * RECEIVES FDA ORPHAN DRUG DESIGNATION (ODD) FOR CER-001 FOR
THE
TREATMENT OF LCAT DEFICIENCY PRESENTING AS KIDNEY DYSFUNCTION
AND/OR OPHTHALMOLOGIC DISEASE

Source text for Eikon:  urn:newsml:reuters.com:*:nNDL6k5XzB
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))